EVH — Evolent Health, Inc.

Evolent Health (EVH) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $496 million, a 9% sequential growth from Q4 2025 (excluding Evolent Care Partners divestiture).
• Adjusted EBITDA: $22 million, in line with expectations.
• Medical Expense Ratio (MER): 93%, improving by 150 basis points from Q4 2025 (excluding ECP).
• Performance Suite Revenue: $323 million, up 26% sequentially, driven by new launches but offset by exchange membership declines.
• Specialty Tech and Services Revenue: $81 million, down 16% sequentially, reflecting exchange membership declines.
• Administrative Services Revenue: $92 million, down 11% quarter-over-quarter due to client terminations.
• Cash Position: $142 million in unrestricted cash; net debt at $792 million.

2. Strategic Updates and Business Highlights

• Successful launches of Performance Suite with Aetna and Highmark, with early indicators of strong clinical intervention and provider engagement metrics.
• Continued demand for oncology solutions, with Evolent positioned as a leader in managing quality and cost in cancer care.
• New contracts announced, including an advanced imaging solution for 4.5 million lives and an expansion of oncology and cardiology solutions expected to generate over $200 million in annual revenue.
• Ongoing efforts to enhance AI and automation capabilities, with a goal to automate approximately 80% of authorization volume.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated range of $2.4 billion to $2.6 billion.
• Adjusted EBITDA Guidance: Reiterated range of $110 million to $140 million.
• MER Expectation: Approximately 93% for the full year, with expected improvements in Q3 due to new contract impacts.
• Anticipated cash flow from operations of $10 million to $20 million for the year, with capital expenditures of $25 million to $30 million.

4. Challenges and Points of Concern

• Declining exchange membership impacting revenue, with a cautious approach assuming a 40% decline in exchange membership for the full year.
• Elevated costs related to servicing exchange members during disenrollment periods, which are expected to normalize later in the year.
• The competitive landscape remains challenging, particularly with Cigna's strategic review of eviCore, indicating potential shifts in market dynamics.

5. Notable Q&A Insights

• Management emphasized the importance of standardization in prior authorizations and the complexity of oncology care, which requires a more nuanced approach.
• The impact of higher prevalence in oncology was noted, particularly in markets with declining membership, but contractual protections are expected to mitigate these effects.
• The company is optimistic about the integration of imaging services into existing Performance Suite contracts, indicating a trend towards fewer, more comprehensive partnerships for health plans.
• Discussions highlighted the ongoing challenges in oncology cost management, with a focus on the need for sophisticated solutions amidst rapid innovation in treatment options.

Overall, Evolent Health reported a solid start to 2026, with strong revenue growth in certain segments but also faced challenges with exchange membership declines and cost pressures. The company remains confident in its strategic direction and long-term growth opportunities.